A next generation immunotherapy company BioNTech SE (NASDAQ:BNTX) is engaged in developing groundbreaking novel therapies for cancer and other severe diseases. The Company was established in 2008. The Company’s root can be traced to Mainz (Germany) and it aspires to be a leading international biotech entity in the space of individualised drugs for cancer treatment.

Load More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK